JPMorgan Chase & Co. Boosts Health Catalyst (NASDAQ:HCAT) Price Target to $13.00

Health Catalyst (NASDAQ:HCAT) had its price objective hoisted by JPMorgan Chase & Co. from $10.00 to $13.00 in a report issued on Wednesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities analysts also recently commented on the company. Cantor Fitzgerald restated an overweight rating and issued a $16.00 price objective on shares of Health Catalyst in a report on Tuesday, August 20th. Wells Fargo & Company cut their price target on shares of Health Catalyst from $14.00 to $13.00 and set an overweight rating on the stock in a report on Friday, May 10th. Piper Sandler decreased their price objective on shares of Health Catalyst from $14.00 to $11.00 and set an overweight rating for the company in a report on Monday, August 26th. Stephens cut their target price on Health Catalyst from $8.00 to $7.00 and set an equal weight rating on the stock in a report on Thursday, August 8th. Finally, Evercore ISI decreased their target price on Health Catalyst from $9.00 to $8.00 and set an outperform rating for the company in a research report on Tuesday, July 9th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Health Catalyst has a consensus rating of Moderate Buy and a consensus target price of $11.42.

Health Catalyst Stock Down 1.2 %

HCAT stock opened at $7.29 on Wednesday. The company has a 50 day moving average of $6.87 and a two-hundred day moving average of $6.93. The company has a market cap of $430.37 million, a price-to-earnings ratio of -3.94 and a beta of 1.31. Health Catalyst has a 12-month low of $5.42 and a 12-month high of $11.98.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business had revenue of $75.90 million during the quarter, compared to analyst estimates of $74.96 million. During the same period last year, the company earned ($0.21) earnings per share. Health Catalyst’s quarterly revenue was up 3.7% compared to the same quarter last year. On average, research analysts anticipate that Health Catalyst will post -0.37 EPS for the current year.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of the firm’s stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the sale, the chief operating officer now directly owns 155,215 shares in the company, valued at approximately $954,572.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the transaction, the chief operating officer now owns 155,215 shares of the company’s stock, valued at approximately $954,572.25. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,672 shares of company stock valued at $197,224. 2.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of HCAT. Nisa Investment Advisors LLC boosted its position in shares of Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after acquiring an additional 5,232 shares in the last quarter. Quarry LP lifted its stake in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the period. Perfromance Wealth Partners LLC acquired a new stake in Health Catalyst during the second quarter valued at approximately $64,000. Mackenzie Financial Corp bought a new stake in shares of Health Catalyst in the 2nd quarter valued at approximately $70,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Health Catalyst in the 1st quarter worth approximately $98,000. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.